Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    "Encephalomyopathy"
Show Display Options
Rank Status Study
1 Recruiting MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study
Condition: Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
Intervention: Biological: Hematopoietic Allogeneic Stem Cells
2 Recruiting Natural History Study - Mitochondrial Disease
Condition: MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier
Intervention:
3 Recruiting The KHENERGY Study
Conditions: Mitochondrial Diseases;   Mitochondrial Myopathies;   Mitochondrial Encephalomyopathies;   MELAS;   MIDD
Interventions: Drug: KH176;   Drug: placebo
4 Completed
Has Results
Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes
Condition: MELAS Syndrome
Interventions: Drug: Idebenone;   Other: Placebo
5 Recruiting MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
Conditions: Mucopolysaccharidosis Disorders;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Alpha-Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Glycoprotein Metabolic Disorders;   Sphingolipidoses;   Recessive Leukodystrophies;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann-Pick B;   Niemann-Pick C Subtype 2;   Sphingomyelin Deficiency;   Peroxisomal Disorders;   Adrenoleukodystrophy With Cerebral Involvement;   Zellweger Syndrome;   Neonatal Adrenoleukodystrophy;   Infantile Refsum Disease;   Acyl-CoA Oxidase Deficiency;   D-Bifunctional Enzyme Deficiency;   Multifunctional Enzyme Deficiency;   Alpha-methylacyl-CoA Racmase Deficiency;   Mitochondrial Neurogastrointestingal Encephalopathy;   Severe Osteopetrosis;   Hereditary Leukoencephalopathy;   Inherited Metabolic Disorders
Interventions: Biological: Stem Cell Transplantation;   Drug: IMD Preparative Regimen;   Drug: Osteopetrosis Only Preparative Regimen;   Drug: Osteopetrosis Haploidentical Only Preparative Regimen;   Drug: cALD SR-A (Standard-Risk, Regimen A);   Drug: cALD SR-B (Standard-Risk, Regimen B);   Drug: cALD HR-D (High-Risk, Regimen C);   Drug: cALD HR-D (High-Risk, Regimen D)
6 Not yet recruiting Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
Conditions: MELAS Syndrome;   Mitochondrial Respiratory Chain Deficiencies
Interventions: Drug: KL1333 25 mg;   Drug: KL1333 50 mg;   Drug: Placebo
7 Completed
Has Results
Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
Condition: MELAS Syndrome
Intervention: Biological: Fluzone®
8 Completed Ketones & Mitochondrial Heteroplasmy
Conditions: MELAS Syndrome;   Mitochondrial Diseases
Intervention: Dietary Supplement: Medium-Chain Triglycerides
9 Completed L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome
Condition: MELAS Syndrome
Intervention: Drug: L-Arginine
10 Completed Nitric Oxide Production in MELAS Syndrome
Condition: MELAS Syndrome
Intervention: Dietary Supplement: Arginine and citrulline supplementations
11 Unknown  Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome
Condition: MELAS Syndrome
Intervention: Drug: Dichloroacetate
12 Unknown  Mitochondrial nt3243 A>G Mutation in Taiwan
Conditions: MELAS Syndrome;   Noninsulin-dependent Diabetes Mellitus With Deafness
Intervention:
13 Completed Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia
Conditions: Mitochondrial Myopathy;   MELAS Syndrome;   Lactic Acidosis
Intervention:
14 Recruiting North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Conditions: Mitochondrial Disorders;   Mitochondrial Genetic Disorders;   Mitochondrial Diseases;   Disorder of Mitochondrial Respiratory Chain Complexes;   Deletion and Duplication of Mitochondrial DNA
Intervention:
15 Completed Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease
Condition: Inherited Mitochondrial Disease, Including Leigh Syndrome
Intervention: Drug: Cysteamine Bitartrate

Study has passed its completion date and status has not been verified in more than two years.